Royal London Asset Management
BMY.RT

Royal London Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Royal London Asset Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-19,459
Closed -$13K – 753
2020
Q4 		$13K Buy
19,459
+7,163
+58% +$15.3K ﹤0.01% 688
2020
Q3 		$25K Sell
12,296
-30,030
-71% -$85.8K ﹤0.01% 625
2020
Q2 		$146K Sell
42,326
-37,298
-47% -$135K ﹤0.01% 645
2020
Q1 		$252K Buy
+79,624
New +$262K ﹤0.01% 642

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Royal London Asset Management's BMY.RT Position: Q1 2021 in Review

Royal London Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 19,459 shares — an estimated $13K sold.

Royal London Asset Management first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $252K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Royal London Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Royal London Asset Management sold 19,459 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $13K.
  • Royal London Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
  • Royal London Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $252K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Royal London Asset Management's 13F filing for Q1 2021, filed 13 Apr 2021.